1988810334497112064

In vivo CAR-T Insights Series

In vivo CAR-T Insights Series (10) — Industrialization & Regulatory Trends in In vivo Gene and Cell Therapy

In vivo CAR-T Insights Series (10) — Industrialization & Regulatory Trends in In vivo Gene and Cell Therapy

As in vivo CAR-T moves closer to clinical reality, the focus is shifting from scientific proof-of-concept to regulatory validation and scalable manufacturing. Global agencies like the FDA and EMA are actively shaping frameworks to ensure both innovation and patient safety in this rapidly evolving field.

In vivo CAR-T Insights Series

Dec 03,2025

In vivo CAR-T Insights Series (9) — Minimizing Off-Target Effects and CRS in In vivo CAR-T Therapy

In vivo CAR-T Insights Series (9) — Minimizing Off-Target Effects and CRS in In vivo CAR-T Therapy

While in vivo CAR-T therapies offer unprecedented potential for non-viral, scalable cell therapy, safety remains the most critical challenge — especially the risks of off-target cytotoxicity and cytokine release syndrome (CRS). Advances in CAR design and delivery precision are paving the way toward safer, controllable in vivo immune engineering.

In vivo CAR-T Insights Series

Dec 03,2025

In vivo CAR-T Insights Series (8) — Immunological Basis of In vivo T Cell Activation and Expansion

In vivo CAR-T Insights Series (8) — Immunological Basis of In vivo T Cell Activation and Expansion

The success of in vivo CAR-T therapy depends not only on efficient gene delivery but also on how effectively T cells become activated and expand within the body. Understanding this process from an immunological perspective is key to achieving functional and durable therapeutic responses.

In vivo CAR-T Insights Series

Dec 03,2025

In vivo CAR-T Insights Series (7) — Evolution of CAR Design in Next-Generation CAR-T Cell Therapy

In vivo CAR-T Insights Series (7) — Evolution of CAR Design in Next-Generation CAR-T Cell Therapy

Antibody discovery is evolving rapidly — and mRNA immunization is reshaping how we generate high-affinity antibodies for next-generation therapies, including Ab-LNP–based in vivo CAR-T platforms.

In vivo CAR-T Insights Series

Dec 03,2025

In vivo CAR-T Insights Series (6) — Antibody Discovery: Why use mRNA for immunity？

In vivo CAR-T Insights Series (6) — Antibody Discovery: Why use mRNA for immunity？

Antibody discovery is evolving rapidly — and mRNA immunization is reshaping how we generate high-affinity antibodies for next-generation therapies, including Ab-LNP–based in vivo CAR-T platforms.

In vivo CAR-T Insights Series

Dec 03,2025

In vivo CAR-T Insights Series (5) — Key Considerations in LNP Encapsulation and Method Comparison

In vivo CAR-T Insights Series (5) — Key Considerations in LNP Encapsulation and Method Comparison

In in vivo CAR-T research, the design and encapsulation strategy of lipid nanoparticles (LNPs) play a decisive role in transfection efficiency and therapeutic outcomes.

In vivo CAR-T Insights Series

Dec 03,2025

< 12 >